MSD has agreed to pay up to $610 million to acquire Caraway Therapeutics, a Cambridge, Massachusetts biotech focusing on neurodegenerative disorders and rare diseases.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl